Annovis Bio Receives Positive Recommendation To Continue Phase 2/3 Trial Of Buntanetap For Alzheimer's Disease Patients From The Independent Data And Safety Monitoring Board
Portfolio Pulse from Benzinga Newsdesk
Annovis Bio, Inc. (NYSE:ANVS) has received a positive safety review from the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer's Disease patients. The DSMB recommended that Annovis Bio continue the trial as originally designed. The trial of buntanetap was initiated in late March 2023 and to date, 281 patients have been recruited out of the planned 320. In phase 2 trials, buntanetap was observed to improve cognition and speed of thinking.
October 30, 2023 | 8:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Annovis Bio's phase 2/3 trial of buntanetap for Alzheimer's Disease patients received a positive safety review from the DSMB, which recommended the continuation of the trial. This is a positive development for the company and its drug candidate.
The positive safety review and recommendation to continue the trial is a significant milestone for Annovis Bio and its drug candidate, buntanetap. This could potentially lead to increased investor confidence and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100